Significant ( p < @ ) changes in anti-double stranded DNA antibodies , complement C@ and C@ , and reductions in B cells were observed with blisibimod.No imbalances in serious adverse events or infections ( @/@ and @/@ ) , deaths ( @/@ and @/@ ) and malignancies ( @/@ and @/@ ) were reported for blisibimod compared with placebo .